Verition Fund Management
MGX icon

Verition Fund Management’s Metagenomi Therapeutics MGX Stock Holding History

Verition Fund Management’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,892
Closed -$20.6K – 4032
2025
Q2 		$20.6K Sell
13,892
-58,233
-81% -$91.2K ﹤0.01% 3564
2025
Q1 		$98.1K Buy
72,125
+19,290
+37% +$46K ﹤0.01% 3157
2024
Q4 		$191K Buy
52,835
+15,160
+40% +$36.6K ﹤0.01% 2993
2024
Q3 		$81.8K Buy
+37,675
New +$131K ﹤0.01% 3021

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Verition Fund Management's MGX Position: Q3 2025 in Review

Verition Fund Management sold out of Metagenomi Therapeutics (MGX) in Q3 2025, closing a stake of 13,892 shares — an estimated $20.6K sold.

Verition Fund Management first reported a position in MGX in Q3 2024 and held it in 4 quarters. The position peaked at $191K in Q4 2024. 58 funds tracked by Wall St. Rank hold MGX as of Q3 2025.

  • Verition Fund Management reported no remaining Metagenomi Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Verition Fund Management sold 13,892 Metagenomi Therapeutics shares in Q3 2025, an estimated $20.6K.
  • Verition Fund Management first reported a position in Metagenomi Therapeutics in Q3 2024 and held it in 4 quarters.
  • Verition Fund Management's Metagenomi Therapeutics position peaked at $191K in Q4 2024.
  • 58 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2025.

Based on Verition Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.